BRPI0413521A - seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares - Google Patents

seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares

Info

Publication number
BRPI0413521A
BRPI0413521A BRPI0413521-0A BRPI0413521A BRPI0413521A BR PI0413521 A BRPI0413521 A BR PI0413521A BR PI0413521 A BRPI0413521 A BR PI0413521A BR PI0413521 A BRPI0413521 A BR PI0413521A
Authority
BR
Brazil
Prior art keywords
amino acid
positively charged
acid residues
penetration
interest
Prior art date
Application number
BRPI0413521-0A
Other languages
English (en)
Inventor
Alexandre Avrameas
Original Assignee
Diatos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03292030A external-priority patent/EP1512696A1/en
Priority claimed from FR0309962A external-priority patent/FR2858772A1/fr
Application filed by Diatos filed Critical Diatos
Publication of BRPI0413521A publication Critical patent/BRPI0413521A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"SEQüêNCIAS DE AMINOáCIDOS QUE FACILITAM A PENETRAçãO DE UMA SUBSTáNCIA DE INTERESSE NAS CéLULAS E/OU NOS NúCLEOS CELULARES". A presente invenção se refere a uma seqüência de aminoácidos adaptados para facilita a penetração de uma substância de interesse nas células e/ou nos núcleos celulares, e que tem a seguinte fórmula (I) ¢(X~ 1~)~ p~ ¢(X)~ 0~ (B)~ n~X B X X B!~ m~ (X~ 2~)~ q~ onde X~ 1~ e X~ 2~ representarem as seqüências de aminoácidos que compreendem de 1 a 20 aminoácidos; p e q representam números inteiros compreendidos entre 0 e 5; B representa um aminoácido básico; X representa um aminoácido não básico e de preferência hidrofóbico, por exemplo, alanina, isoleucina, leucina, metionina, fenilalanina, triptofano, valina ou tirosina; n vale 2 ou 3; m vale entre 1 e 4; o vale 0 ou 1.
BRPI0413521-0A 2003-08-14 2004-08-13 seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares BRPI0413521A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03292030A EP1512696A1 (en) 2003-08-14 2003-08-14 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
FR0309962A FR2858772A1 (fr) 2003-08-14 2003-08-14 Composition anti bacterienne, plus particulierement contre les bacteries gram negatif, comprenant un peptide et un agent anti-bacterien avantageusement hydrophobe
PCT/IB2004/002936 WO2005016960A2 (en) 2003-08-14 2004-08-13 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei

Publications (1)

Publication Number Publication Date
BRPI0413521A true BRPI0413521A (pt) 2006-10-10

Family

ID=34196165

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413521-0A BRPI0413521A (pt) 2003-08-14 2004-08-13 seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares

Country Status (12)

Country Link
US (2) US7544664B2 (pt)
EP (2) EP1653989B1 (pt)
JP (2) JP4755591B2 (pt)
AT (1) ATE533786T1 (pt)
AU (1) AU2004265159B2 (pt)
BR (1) BRPI0413521A (pt)
CA (2) CA2535670A1 (pt)
DE (1) DE602004022056D1 (pt)
DK (1) DK1653989T3 (pt)
ES (2) ES2378312T3 (pt)
IL (1) IL173362A0 (pt)
WO (2) WO2005016960A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
ATE533786T1 (de) 2003-08-14 2011-12-15 Cellectis Aminosäuresequenzen, die das eindringen einer substanz von interesse in zellen und/oder zellkerne erleichtern
EP1797901A1 (en) 2005-12-16 2007-06-20 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
JP2009519033A (ja) * 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
US20090312265A1 (en) * 2006-02-10 2009-12-17 Dermagen Ab Novel antimicrobial peptides and use thereof
JP5313867B2 (ja) * 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
BRPI0709447A2 (pt) * 2006-03-30 2011-07-12 Diatos Sa conjugado, composição farmacêutica, uso e composto
EP1867661A1 (en) * 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
CA2791116A1 (en) 2010-02-26 2011-09-01 Olivier Danos Use of endonucleases for inserting transgenes into safe harbor loci
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
JP6074686B2 (ja) * 2011-09-15 2017-02-08 和歌山県 ペプチド含有ポリマー、及び繊維へのペプチド固定化方法
CN102665151B (zh) * 2012-04-24 2014-12-03 烽火通信科技股份有限公司 一种分组传送网中sdh业务dcc开销的处理方法及装置
US9765220B2 (en) 2013-08-22 2017-09-19 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
SG10201811729PA (en) * 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
WO2016138461A1 (en) 2015-02-26 2016-09-01 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
US11123400B2 (en) 2015-09-17 2021-09-21 Seoul National University R&Db Foundation Broken or folded helical peptide or peptide analog exhibiting antimicrobial activity against gram-negative bacteria, and use thereof
WO2017048092A1 (ko) * 2015-09-17 2017-03-23 서울대학교산학협력단 그람 음성균에 대한 항균 활성을 나타내는 끊어진 또는 꺾어진 나선 펩타이드 또는 펩타이드 유사체 및 이의 용도
EP3436529A1 (en) 2016-04-01 2019-02-06 Sony Corporation Ultra bright dimeric or polymeric dyes
WO2017197014A2 (en) 2016-05-10 2017-11-16 Sony Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
US11370922B2 (en) 2016-05-10 2022-06-28 Sony Corporation Ultra bright polymeric dyes with peptide backbones
BR112018073199A2 (pt) 2016-05-11 2019-04-16 Sony Corporation corantes diméricos ou poliméricos ultrabrilhantes
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
KR20200135424A (ko) 2018-03-19 2020-12-02 소니 주식회사 형광 신호 향상을 위한 2가 금속의 사용
US20210032474A1 (en) 2018-03-21 2021-02-04 Sony Corporation Polymeric tandem dyes with linker groups
KR102486779B1 (ko) 2019-09-26 2023-01-12 소니그룹주식회사 링커 그룹을 갖는 중합체성 탠덤 염료

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4526888A (en) * 1983-04-29 1985-07-02 Bristol-Myers Company Nephrotoxicity inhibitors for aminoglycoside antibiotics
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5254535A (en) * 1989-04-17 1993-10-19 The Children's Hospital Of Pennsylvania Composition and treatment with biologically active peptides and antibiotic
DK455789D0 (da) 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO1994028921A1 (en) * 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
WO1996006632A1 (en) 1994-09-01 1996-03-07 Allied Medical Research Associates Compositions and methods for delivery of polypeptides
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
WO1996008274A2 (en) 1994-09-13 1996-03-21 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
US5834430A (en) * 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
FR2736642B1 (fr) 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US6066485A (en) 1996-03-21 2000-05-23 New York University Growth factor inducible serine/threonine phosphatase fin13
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US5967195A (en) 1997-08-01 1999-10-19 Weavexx Corporation Multi-layer forming fabric with stitching yarn pairs integrated into papermaking surface
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
WO1999032136A1 (en) 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Chimeric proteins for the treatment of diabetes
AU755564B2 (en) 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2000045831A1 (en) 1999-02-02 2000-08-10 Thomas Jefferson University Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans
US6855801B1 (en) * 1999-02-02 2005-02-15 Thomas Jefferson University Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans
JP4513145B2 (ja) * 1999-09-07 2010-07-28 ソニー株式会社 半導体装置の製造方法および研磨方法
FR2805821B1 (fr) * 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
US8003595B2 (en) * 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
AU2003223923A1 (en) * 2002-05-01 2003-11-17 Pantheco A/S Peptide nucleic acid conjugates with transporter peptides
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20050239688A1 (en) 2002-07-24 2005-10-27 Anne-Marie Fernandez Method for the synthesis of anthracycline-peptide conjugates
ATE533786T1 (de) 2003-08-14 2011-12-15 Cellectis Aminosäuresequenzen, die das eindringen einer substanz von interesse in zellen und/oder zellkerne erleichtern
US20060281897A1 (en) 2003-08-22 2006-12-14 Andre Trouet Potentialization of the activation of high molecular weight prodrugs

Also Published As

Publication number Publication date
DK1653989T3 (da) 2009-11-23
JP2007529194A (ja) 2007-10-25
WO2005018650A3 (fr) 2005-06-16
WO2005016960A3 (en) 2005-04-07
JP4633055B2 (ja) 2011-02-16
WO2005016960A2 (en) 2005-02-24
CA2535745A1 (fr) 2005-03-03
WO2005018650A2 (fr) 2005-03-03
US8293700B2 (en) 2012-10-23
AU2004265159B2 (en) 2010-08-19
CA2535670A1 (en) 2005-02-24
EP1654285A2 (en) 2006-05-10
EP1653989B1 (fr) 2009-07-15
AU2004265159A1 (en) 2005-02-24
ES2330115T3 (es) 2009-12-04
EP1653989A2 (fr) 2006-05-10
US20070042492A1 (en) 2007-02-22
JP4755591B2 (ja) 2011-08-24
US7544664B2 (en) 2009-06-09
JP2007502262A (ja) 2007-02-08
ES2378312T3 (es) 2012-04-11
EP1654285B1 (en) 2011-11-16
DE602004022056D1 (de) 2009-08-27
ATE533786T1 (de) 2011-12-15
IL173362A0 (en) 2006-06-11
US20070259813A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
BRPI0413521A (pt) seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
BRPI0620806B8 (pt) complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição
WO2001079465A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
WO2005000193A3 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
EP0921818A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON JAGGED / NOTCH PROTEINS AND AMINO ACIDS
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
AU5243901A (en) Repair of nerve damage
DE69821376D1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
DE69808743T2 (de) Netrinrezeptoren
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
AU2003287115A1 (en) Fluorescent proteins from copepoda species and methods for using same
EP1080724A4 (en) COMPOSITIONS FOR REDUCING MTP ACTIVITY
WO2008144351A3 (en) Compositions and methods for inhibiting inducible t cell kinase (itk) and treating asthma and bronchial inflammations
WO2002022661A3 (en) NOVEL PDEs AND USES THEREOF
AR013801A1 (es) Nuevas moleculas de acido nucleico aislada, una proteina de epoxido hidrolasa de artropodo hematofago aislada, una formulacion de proteinas deepoxido hidrolasa de pulga, una composicion terapeutica que reduce la infestacion de ectoparasitos hematofagos; uso de dicha composicion para la
WO2002053586A3 (en) Inhibitor of apoptosis proteins and nucleic acids and methods for making and using them
ES8802556A1 (es) Procedimiento para controlar el desprendimiento de microorganismos adheridos a superficies
ATE379967T1 (de) Nukleinsäuren kodierend miteinander verbundene chromo/fluoreszenzdomänen und verfahren zu ihrer verwendung
WO1999055885A3 (en) Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
WO2002031127A3 (en) Cloning and recombinant expression of mammalian group xii secreted phospholipase a¿2?
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/10 (2006.01), A61K 31/7048 (2006.01), A61K